107年健康老化研究中心 第二次老化相關疾病研究團隊會議-5月25日(五)
報告摘要：
Cardiovascular disease is second cause of mortality, with around 11.1% of the Taiwan population. As the end stage of cardiovascular disease, heart failure (HF) suffers higher morbidity and poor prognosis. According to the preliminary report of the National Health Insurance Research Database, eleven thousand five hundred people have used medical services with HF diagnosis (ICD 9 code 428) in Taiwan. Hence, healthcare for HF is a great burden of medical system. This proposal integrates six research programs that include from bio/functional markers to clinical therapeutics in cardiovascular disorders (CVD) that included HF as follows: 1) to establish the research platform of multi-biomarkers for analyzing oxidative stress profiles, metabolomics, and mycardiocyte stress/injury in CVD and HF progressions; 2) to establish the research platform of systemic physiological markers for evaluating central/peripheral hemorheological characterics and atherothrombosis/ angiogenesis-related variables in CVD and HF progressions; 3) to dissect molecular mechanisms concerning involvement of oxidative stress/inflammation in CVD and HF progressions for creating opportunities for the development of therapeutic strategies beneficial for CVD and HF; 4) to develop the animal models in CVD and HF for employing novel developments of tissue engineering and cardiac rehabilitation; 5) to develop a novel technology of vascular conduit engineering for constructing an artificial vessel from an autologous source and non-invasively; and 6) to design the “safe and effective” cardiac rehabilitation for promoting aerobic fitness and minimizing the hemodynamic limitations and vascular thrombotic events. By elucidating the relationship between biomarkers and pathogenesis in CVD and HF, the novel strategies that involve suitable medicine and rehabilitation will be developed to prevent early hemodynamic dysfunction and thrombotic events, further retarding CVD and HF progressions.